Novartis Albania is reimagining medicine by delivering innovative treatments, advancing research and development, supporting ...

About Novartis Immunology At Novartis, we’re advancing bold science with the goal of bringing relief and a renewed sense of hope to people living with autoimmune diseases. Building on our legacy of ...

New Cosentyx® (secukinumab) data from REPLENISH, largest ever global Phase III trial in polymyalgia rheumatica, to be highlighted in oral session New ianalumab interim results from Sjögren’s Phase III ...

Analyses from REMIX-1 & -2 studies on CSU disease control and early symptom relief will be presented Phase II data evaluating safety and efficacy results of remibrutinib for treatment of peanut ...

Novartis today announced that it has entered into a global license and collaboration agreement with PTC Therapeutics for PTC518, an HTT mRNA splice modulator with the potential to become the first ...

On April 9, 2019 Alcon becomes a separately traded company. Novartis and Alcon are now positioned to capitalize on significant growth opportunities and focus resources on their respective businesses ...

Novartis works with the patient community around the world to discover new ways to improve and extend people’s lives. Novartis works closely with healthcare professionals around the world to support ...

At Novartis, we innovate, develop and operate on a vast scale. You can be part of it. Join our creative community of professionals and you will find opportunities to make an unprecedented impact – on ...

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...

A Phase 2, Randomized, Open-label, Controlled Study to Evaluate the Efficacy and Safety of Rapcabtagene Autoleucel Versus Comparator in Participants With Severe Refractory Idiopathic Inflammatory ...

The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \ [225Ac\]Ac-ETN029 and the safety and imaging properties of \ [111In\]In-ETN029 in patients ...

This report covers information on nonfinancial matters deemed material and in scope of our reporting obligations under the Swiss Code of Obligations (SCO), as well as our due diligence and reporting ...